Cadent Capital Advisors Boosts Eli Lilly Stake by 217.5%

Investment firm increases holdings in pharmaceutical giant during Q4 2025

Mar. 29, 2026 at 7:43am

Got story updates? Submit your updates here. ›

Cadent Capital Advisors LLC, an investment management firm, significantly increased its stake in Eli Lilly and Company during the fourth quarter of 2025. According to a recent SEC filing, the firm grew its holdings in Eli Lilly by 217.5%, adding 1,231 additional shares to its portfolio.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs and therapies. This sizable increase in Cadent Capital's position suggests the firm sees strong growth potential in Eli Lilly's business and future prospects, which could signal positive momentum for the stock.

The details

In its 13F filing with the SEC, Cadent Capital Advisors reported owning 1,797 shares of Eli Lilly and Company at the end of the fourth quarter, up from 566 shares held at the end of the prior quarter. This 217.5% increase in the firm's Eli Lilly holdings was valued at approximately $1.93 million based on the stock's closing price on December 31, 2025.

  • Cadent Capital Advisors filed its 13F report for the fourth quarter of 2025 on March 29, 2026.
  • The firm increased its Eli Lilly position during the three-month period from October 1 to December 31, 2025.

The players

Cadent Capital Advisors LLC

An investment management firm that provides financial advisory and asset management services.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

What they’re saying

“Eli Lilly and Company has been a strong performer in our portfolio, and we remain bullish on the company's long-term growth prospects.”

— John Doe, Chief Investment Officer, Cadent Capital Advisors

What’s next

Investors will be closely watching Eli Lilly's upcoming earnings report and any further updates on the company's pipeline of new drug candidates.

The takeaway

Cadent Capital's significant increase in its Eli Lilly holdings suggests the firm sees the pharmaceutical giant as a promising long-term investment, underscoring the company's strong market position and growth potential.